Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$1.95 USD
+0.02 (1.04%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Cognition Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 51 | 44 | 29 | 17 | 0 |
Income After Depreciation & Amortization | -51 | -44 | -29 | -17 | 0 |
Non-Operating Income | 25 | 22 | 18 | 11 | NA |
Interest Expense | 0 | 0 | 1 | 2 | NA |
Pretax Income | -26 | -21 | -12 | -8 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -26 | -21 | -12 | -8 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -26 | -21 | -12 | -8 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -50 | -43 | -28 | -16 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 1 | NA |
Income After Depreciation & Amortization | -51 | -44 | -29 | -17 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 30.03 | 23.64 | 5.19 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.86 | -0.91 | -3.13 | NA | NA |
Diluted Net EPS (GAAP) | -0.86 | -0.91 | -3.13 | NA | NA |
Fiscal Year end for Cognition Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 15.19 | 14.75 | 11.82 | 8.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -15.19 | -14.75 | -11.82 | -8.97 |
Non-Operating Income | NA | 7.06 | 8.00 | 7.10 | 2.81 |
Interest Expense | NA | 0.01 | 0.00 | 0.01 | 0.01 |
Pretax Income | NA | -8.14 | -6.75 | -4.73 | -6.17 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -8.14 | -6.75 | -4.73 | -6.17 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -8.14 | -6.75 | -4.73 | -6.17 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 30.15 | 30.37 | 29.62 | 29.10 |
Diluted EPS Before Non-Recurring Items | NA | -0.27 | -0.22 | -0.16 | -0.21 |
Diluted Net EPS (GAAP) | NA | -0.27 | -0.22 | -0.16 | -0.21 |